Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised Control Trial (RCT) to Investigate the Effectiveness of a Selfmanagement Intervention and Personalised Genetic Risk Information to Reduce Risk of Coronary Heart Disease in Patients With Type 2 Diabetes.
Brief Summary: The primary objective of the CORDIA study is to use an effective evidence-based self-management intervention (SMI) for type 2 diabetes, with and without a novel test to give a personalised genetic and lifestyle risk of coronary heart disease, to examine their capacity to reduce the risk of coronary heart disease (CHD) and improve diabetes management in primary care patients with type 2 diabetes. The effect of these interventions on clinical, behavioural and psychological outcomes will be investigated.


Options:
A: Participants originally enrolled in the Diabetes Control and Complications Trial (DCCT) (N01-DK-6-2204-A).
B: Inclusion Criteria:

* Documented diagnosis of hypertension.
* Adequate English fluency (both verbal and written).

Exclusion Criteria:

* Systolic BP level \>220 mmHg or diastolic BP level \>110 mmHg on screening BP measurement (WatchBP \[Microlife Corp., Widnau, Switzerland\]).
* Heart failure
* Severe cognitive impairment, defined as a score of ≥ 5 on the Short Portable Mental Status Questionnaire.
* Severe depression (Patient Health Questionnaire \[PHQ-8\] ≥15).
* Foreshortened life expectancy (\<1y).
* Participation in a concurrent cardiovascular trial.
* Currently receiving case management services for cardiovascular risk factor control.
C: Inclusion Criteria:

* diagnosed with IGT using OGTT, at least 55 years old, sedentary (elevated HR \& SOB \< 3x/wk for \<30min each occasion), good overall health, willing to exercise at least 4 days/week for 6 mos

Exclusion Criteria:

* Significant neurologic disease that might affect cognition, such as AD, stroke, Parkinson's disease, multiple sclerosis, or severe head injury with loss of consciousness; significant medical illness or organ failure, such as liver disease, significant elevations in liver function tests, kidney disease, and uncontrolled hypertension (BP \> 140/90 on medication); cardiovascular disease defined as any acute cardiovascular abnormality, such as new or unstable angina, uncontrolled irregular heart beat (treated a-fib and occasional PVC's are OK) or symptomatic heart failure, acute shortness of breath for any reason, or clinically significant edema; chronic lung disease, (COPD/emphysema); musculoskeletal impairment (impaired walking); current use of anti-psychotic, anti-convulsant, anti-coagulant, sedative medication, or cognition-enhancing medications; current or previous use of hypoglycemic agents or insulin.
D: Inclusion Criteria:

* Males and females aged 25-70 years diagnosed with type 2 diabetes
* White, Afro-Caribbean or Asian-Indian ethnicity
* Most previous or baseline HbA1c ≥6.5% or 48 mmol/mol
* Fluency in written and spoken English

Exclusion Criteria:

* Diagnosis of ischemic heart disease, stroke, Transient Ischaemic Attack (TIA) or peripheral vascular disease
* Serious or enduring mental health problems that would prevent the patient from completing the study
* Currently receiving treatment for a life-threatening condition (e.g., cancer) or in the terminal stages of a condition
* Adults who cannot consent for themselves

Answer: D